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Glutamic acid decarboxylase of 65 kDa (GAD65) antibodies have been reported in
a variety of neurological disorders such as stiff-person syndrome (SPS), sporadic
ataxia and some cases of epilepsy. Since the target is believed to be the
cytoplasmic enzyme GAD65, the key enzyme of γ-aminobutyric acid (GABA)
synthesis, the pathophysiological role of these antibodies is poorly understood.
Here, we stereotactically injected human cerebrospinal fluid (CSF) containing
GAD65-antibodies into the hippocampus of rats in vivo and then prepared
hippocampal slices 1–2 days after post-operative recovery. We characterized
both evoked and spontaneous GABAergic transmission in vitro using sharp
microelectrode and patch-clamp recordings in CA1 neurons. Intracellular recordings
with sharp microelectrodes from CA1 neurons showed that evoked GABAAR-
or GABABR-mediated inhibitory postsynaptic potentials (IPSP) remained unaltered
in anti-GAD65 tissue. These results were confirmed with patch-clamp recordings
showing no difference in evoked gabazine-sensitive inhibitory postsynaptic currents
(IPSCs). In addition, spontaneous IPSCs also showed no difference between
anti-GAD65 tissue and controls with respect to the mean frequency, the mean
amplitude and the sIPSC distribution. In conclusion, stereotactic injection of
GAD65-antibodies into the hippocampus leaves evoked and spontaneous GABAergic
synaptic transmission intact. Hence, dysfunction of the inhibitory GABAergic
system does not appear to be the major mechanism of epileptogenicity in this
disease.
Keywords: GAD65-antibodies, GABA receptor, autoimmune encephalitis, CSF, IPSC, IPSP
INTRODUCTION
Autoimmune encephalitis is increasingly recognized in patients with otherwise unexplained
temporal lobe epilepsy. Immune-mediated encephalitides were usually considered to be
paraneoplastic in origin, first described in 1960 (Brierley et al., 1960), and many reported cases
were associated with specific autoantibodies—mainly to Hu (anti-neuronal nuclear antibody-1,
ANNA-1), in patients with lung cancer (Dalmau et al., 1992; Alamowitch et al., 1997; Graus et al.,
2001), to Ma2 (paraneoplastic antigen Ma2) in patients with testicular tumors (Voltz et al., 1999),
to CRMP5/CV2 (collapsin response mediator protein 5) in patients with thymomas (Antoine
et al., 1995) or to NMDA receptors in patients with ovarian teratomas (Dalmau et al., 2007).
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In addition, cases of non-paraneoplastic autoimmune
encephalitis have been described (Bien et al., 2000; Mori
et al., 2002), associated with systemic autoimmune disorders,
autoantibodies against cell membrane antigens such as
voltage-gated potassium channels (Buckley et al., 2001;
Schott et al., 2003; Vincent et al., 2004) later refined as
antibodies to elements of the potassium channel complex,
namely leucine-rich, glioma inactivated 1 (LGI1) and contactin-
associated protein 2 (CASPR2; Irani et al., 2010; Lai et al.,
2010; Lancaster et al., 2011), and autoantibodies against
intracellular antigens such as glutamic acid decarboxylase (GAD;
Saiz et al., 2008; Malter et al., 2010).
GAD-antibodies were initially identified in the serum
and cerebrospinal fluid (CSF) of patients with stiff-person
syndrome (SPS; Solimena et al., 1988). This syndrome often
occurs in association with other autoimmune diseases, mainly
type 1 diabetes mellitus (DM1; Baekkeskov et al., 1990). GAD-
antibodies are present in about 80% of newly diagnosed DM1
patients, although the levels are usually 100-fold higher in SPS
than in DM1 (Meinck et al., 2001). GAD-antibodies were also
reported in a subgroup of patients with late-onset isolated
cerebellar ataxia (Honnorat et al., 2001), and in the last years
more frequently in patients with limbic encephalitis and epilepsy
(Saiz et al., 2008). GAD-antibodies may be found in patients
with epilepsy in two different settings (Bien and Scheffer, 2011):
(i) acute/subacute onset of seizures accompanied by variable
degrees of cognitive and psychiatric disturbance, typically
in association with MRI evidence of inflammation of mesial
temporal structures (limbic encephalitis; Malter et al., 2010);
and (ii) in patients with chronic epilepsy without clinical or
MRI evidence of active CNS inflammation (Liimatainen et al.,
2010).
As the primary target is believed to be GAD65 which
is a cytoplasmic enzyme, the pathophysiological role of
GAD-antibodies is still unresolved (in many patients, the
antibodies are also directed to GAD67; isolated GAD67
antibodies are a very rare exception). GAD is the rate-
limiting enzyme for γ-aminobutyric acid (GABA) synthesis
that catalyzes the conversion of glutamic acid to the
inhibitory neurotransmitter GABA, and is diffusely present
in the central nervous system (CNS; Lernmark, 1996).
One attractive hypothesis of the pathophysiological role
of GAD-antibodies is the inhibition of synaptic GAD
activity, leading to a decrease in GABA synthesis in
nerve terminals; an alternative assumption is interference
with GABA release (Dinkel et al., 1998; Mitoma et al.,
2000). Hence, altered GABAergic transmission could
lead to increased neuronal excitability and lower seizure
threshold.
It is not known whether GAD65-antibodies play a
pathophysiologically relevant role in vivo. Therefore, we
performed stereotactic injection of CSF containing GAD65-
antibodies into the rat hippocampus in order to study
GABAergic transmission in the CA1 region of hippocampal
slices. We found that GAD65-antibodies applied in vivo
did not alter GABAergic synaptic transmission in hippocampal
slices.
MATERIALS AND METHODS
Stereotactic Intrahippocampal Injection In
Vivo
Bilateral stereotactic injection of CSF samples into the
hippocampus was performed in 2-month-old female Wistar
rats (190–260 g, Charles River, Sulzfeld, Germany). CSF samples
containing high-titer GAD65-antibodies were obtained from
three patients with focal epilepsy due to limbic encephalitis
(all female; 18, 27 and 50 years old). GAD65-antibodies
were detected by indirect immune-techniques by congruent
GAD65 specific signals on mouse brain, transfected cells and
immune-dot-blot (all from Euroimmun, Lübeck, Germany).
Titration was done on cell based assays in dilution steps of 1:2
and multiples. All titers were higher than 1:250. All patients
gave informed consent to use the CSF samples for scientific
purposes. For control experiments, sterile saline was used for
stereotactic injection. All animal procedures were approved by
the local Animal Welfare committee and conformed to national
and international guidelines on the ethical use of animals
(European Council Directive 86/609/EEC, approved by the
Regional Authorities of Agriculture, Food Safety and Fishery
Mecklenburg-West Pomerania, No. 7221.3–1.1–017/11). All
efforts were made to minimize animal suffering and to reduce
the number of animals used.
Surgery was performed in animals anesthetized with
S-ketamine (100 mg/kg i.p.) and xylazine (15 mg/kg i.p.)
and mounted on a stereotactic frame (Narishige, Tokyo,
Japan). The injection site (relative to bregma) was optimized
using ink injection and two sets of coordinates were used for
animals < 220 g (5.2 mm posterior, ±4.3 mm lateral, 4.8 mm
deep) and animals > 220 g (4.7 mm posterior, ±4.5 mm lateral,
6.0 mm deep). The injection of 5 µl of native non-diluted
CSF in 10 steps of 0.5 µl every 2 min into both hippocampi
was performed with a Hamilton syringe (75 N; Hamilton AG,
Bonaduz, Switzerland). Following the last 0.5-µl-step, the syringe
was left in situ for another 2 min to optimize CSF intrusion
into the brain parenchyma. After surgery, the rats recovered
quickly and were sacrificed 1–2 days following stereotactic
injection.
Hippocampal Slice Preparation
After deep anesthesia with diethyl ether (Mallinckrodt Baker,
Deventer, Netherlands), rats were decapitated, and the brains
were dissected out quickly and submerged into oxygenated iced
sucrose-based dissection fluid containing (in mM) NaCl 87,
sucrose 75, KCl 2.5, NaHCO3 25, NaH2PO4 1.25, CaCl2 0.5,
MgCl2 7, and glucose 10, pH 7.4, osmolarity 300–310 mosmol/kg
H2O. Transversal horizontal brain slices (400 µm) of the
hippocampus were prepared using a vibratome (Integraslice
7550MM, Campden Instruments, Loughborough, UK), and then
transferred into a storage chamber containing sucrose-based
dissection solution. Slices were continuously gassed with 95%
O2 and 5% CO2 to maintain the pH at 7.4 and allowed to
recover at room temperature for at least 1 h before being
placed into an interface chamber (BSC HT, Harvard Apparatus,
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Holliston, USA) perfused with standard artificial cerebrospinal
fluid (ACSF) containing (in mM) NaCl 125, KCl 3, NaHCO3 21,
NaH2PO4 1.25, CaCl2 2.5, MgCl2 1.0 and glucose 13, pH 7.4,
osmolarity 295–305 mosmol/kg H2O (2 ml/min). The recording
temperature was maintained at 32◦C (TC-10, npi electronic,
Tamm, Germany).
Intracellular Recordings
Sharp microelectrode recordings were used to study
GABAA-receptor and GABAB-receptor-mediated inhibitory
postsynaptic potentials (IPSPs). To this end, CA1 pyramidal
cells were impaled with a borosilicate glass microelectrode
(60–130 M, pulled with P-97, Sutter Instrument, Novato,
USA and filled with 3 M potassium acetate and 0.3 M KCl)
by using an SEC-10L amplifier (npi electronic). A unipolar
stimulation electrode placed into the CA1 region, nearby the
recording electrode, was used to stimulate adjacent interneurons.
GABA-mediated IPSPs were isolated pharmacologically in the
presence of the NMDA-receptor blocker D-AP5 (50 µM) and
the AMPA receptor blocker 6-cyano-7-nitroquinoxaline-2,
3-dione disodium (CNQX, 10 µM, both from Tocris). Under
these conditions, resting membrane potential, membrane
resistance, and membrane time constant were determined.
Membrane resistance was calculated as the slope of the steady-
state current-voltage relationship obtained by hyperpolarizing
current injection (ranging from −1.4 to +1.4 nA in 100-pA-
steps for 600 ms). Membrane time constant was calculated
as the average time constant during the hyperpolarizing
steps. Increasing stimulation strength (from 20 to 400 µA
in 20-µA-steps every 20 s) applied to interneurons evoked
increasing amplitudes of GABAAR- and GABABR- mediated
IPSPs.
Patch-Clamp Recordings
Patch-clamp recordings of GABAA receptor-mediated inhibitory
postsynaptic currents (IPSCs) were performed to obtain
kinetic data of GABAergic transmission. Recordings from CA1
pyramidal cells were performed in the whole-cell mode with
recording electrodes (4–8 M) filled with internal solution
containing (in mM) CsCl 145, HEPES 20, NaCl 2, Mg-ATP
2, GTP 0.3, KOH-EGTA 0.2 (pH 7.2, adjusted with KOH;
310 mosmol/kg H2O). QX-314 (5 mM) added to the internal
solution prevented the cells from voltage-dependent spiking.
In order to isolate GABAergic currents, the NMDA-receptor
blocker D-AP5 (50 µM) and the AMPA receptor blocker CNQX
(10 µM, both from Tocris Bioscience, Bristol, UK) were added
to the ACSF before the patch pipette was lowered to the slice.
The stimulation electrode was placed nearby the recording
electrode to activate interneurons. GABAergic currents were
recorded at room temperature (24◦C) in voltage-clamp mode
(holding potential −50 mV) with a patch-clamp amplifier (ELC
03 × S, npi), low-pass filtered at 2 kHz, digitized at 10 kHz
(Micro1401, CED, Cambridge Electronic Design, Cambridge,
UK) and analyzed with Signal 2.16 (CED). Series resistance was
monitored, and cells were excluded from analysis when series
changes in series resistance exceeded 100% or 30 M. Increasing
stimulation strength (from 0.05 to 0.5mA in 0.05-mA-steps every
10 s) applied to interneurons evoked increasing amplitudes of
GABAAR-mediated IPSCs. In addition, cells were held at varying
membrane potentials (from −50 to +20 mV in 10-mV-steps)
during stimulation in order to measure the variation coefficient
and the reversal potential. In order to measure time constants
for rise and decay (τrise and τdecay), latency and charge (area
under the curve), we averaged 25 GABAAR-mediated IPSCs
at half-maximum amplitude. To assess the duration of the
IPSC, we determined the width at 10% of peak amplitude.
Variability in GABAAR-mediated IPSCs was expressed as the
coefficient of variation (CV), defined as the ratio of the
standard error to the mean of the IPSC amplitudes. Membrane
resistance was calculated as the slope of the steady-state voltage-
current relationship obtained by hyperpolarization (ranging
from −60 to −90 mV in 5-mV-steps for 300 ms). Finally,
gabazine (5 µM) was administered to confirm GABAA-receptor
dependence.
Data Processing and Statistical Analysis
Digitization and offline data processing were performed with
the CED package (Micro1401 analog-to-digital converter, Signal
2.16 Software, all from CED). All data are expressed as
means ± standard error of the mean (SEM). Student’s t test or
analysis of variance (ANOVA) were used to test for statistical
significance. The level of significance is set to 0.05.
RESULTS
Evoked GABAergic Transmission is Intact
in Anti-GAD65 Tissue
To study the role of GAD65-antibodies in evoked GABAergic
transmission, we stereotactically injected GAD65 antibodies into
the hippocampus in vivo, and then recorded IPSP in slices
prepared 1–2 days after surgery using sharp microelectrode
recordings from CA1 pyramidal cells. GABA receptor-mediated
IPSPs in CA1 neurons were evoked by focal stimulation applied
at increasing intensities (20–400 µA in 20-µA-steps) under
blockade of glutamatergic transmission (CNQX and D-AP5 to
block AMPA and NMDA receptors, respectively). GABAAR-
and GABABR-mediated components were distinguished by
their kinetics (see lowercase letters in Figure 1A). In five
cells, we confirmed gabazine sensitivity (1 µM) of the first
component (indicated by ‘‘c’’ in Figure 1A) demonstrating
GABAAR-dependence (Anti-GAD: −0.2 ± 0.0 mV, n = 2;
Control: −0.4 ± 0.2 mV, n = 3). Input-output relationships
of GABAAR- and GABABR-mediated IPSPs from rats injected
with anti-GAD65-CSF vs. control were not significantly different
(Figures 1B,C). These results show that in vivo stereotactic
injection of GAD65-antibodies into the hippocampus does not
cause any depression of GABAergic synaptic transmission in
vitro. Importantly, also the resting membrane potential observed
in these intracellular recordings was almost identical in anti-
GAD65-treated and control tissues (Table 1). However, there was
a tendency towards higher membrane resistance in cells from
anti-GAD65-treated animals that might hint at a mildly impaired
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FIGURE 1 | GABAA and GABAB receptor-mediated inhibitory
postsynaptic potentials (IPSPs) are intact in anti-GAD65 tissue.
(A) Sample trace of an intracellular recording evoked by increased near field
stimulation showing the resting membrane potential (a), the stimulus artifact
(b), the fast GABAAR-mediated IPSP component (c) and the slow
GABABR-mediated IPSP component (d). (B) The input-output relationship of
the GABAAR-mediated IPSP component did not reveal differences between
anti-GAD65-treated animals and controls. (C) The input-output curve of the
GABABR-mediated IPSP component was also not different between
anti-GAD65-injected and control animals.
tonic GABAergic steady-state conductance in these cells. By
contrast, experiments with gabazine to block GABAAR IPSP
components showed that the gabazine-induced depolarization
was stronger in cells from anti-GAD65-treated tissue than in
control cells as assessed by amplitude of current injection
necessary to hold a membrane potential of−70 mV (Anti-GAD:
−144 ± 10 pA, n = 2; Control: −51 ± 2 pA, n = 3, P < 0.05),
which in turn argues against impaired tonic GABA inhibition.
Thus, we conclude from our sharp microelectrode data that
evoked GABAergic inhibition in anti-GAD65-treated tissue is
left intact.
Since subtle anti-GAD mediated changes in GABAAR
kinetics can be missed in sharp intracellular recordings, we
next performed whole-cell patch-clamp recordings from CA1
pyramidal cells. GABAAR-mediated IPSCs were isolated by
adding D-AP5 (5 µM) and CNQX (10 µM) and using an
TABLE 1 | CA1 pyramidal cell properties (intracellular recordings).
Cell property Control (n = 9) Anti-GAD (n = 8) P value
Resting membrane potential −68 ± 1 mV −67 ± 1 mV 0.72
Membrane resistance 44 ± 4 M 55 ± 4 M 0.07
Time constant 11.8 ± 0.5 ms 12.6 ± 0.9 ms 0.47
Voltage sag (injection of −1.0 nA) −5.1 ± 0.9 mV −7.4 ± 0.9 mV 0.12
AHP (injection of 0.5 nA) −5.6 ± 0.9 mV −6.4 ± 1.0 mV 0.57
AP number (injection of 0.5 nA) 5.1 ± 0.6 6.2 ± 0.8 0.28
almost K+−free (0.2 mM) intracellular solution. Figure 2A
shows a representative trace of an isolated GABAAR-mediated
IPSC which was abolished by application of gabazine indicating
GABAAR-dependence (5 µM, superimposed gray trace in
Figure 2A). Importantly, there was no difference in gabazine
sensitivity between anti-GAD65-treated and control tissue
(Figure 2B). Increasing stimulation strength raised IPSC
amplitudes, and the input-output relationship under voltage-
clamp conditions confirmed the IPSP data obtained with sharp
microelectrodes (Figure 2C). Moreover, the reversal potential
of GABAAR-mediated IPSCs was indistinguishable between
anti-GAD65-treated animals and controls (Figure 2D). It is
important to note that with respect to GABAAR-mediated
IPSC kinetics, no significant difference could be observed (τrise,
τdecay, IPSC width at 10%, Table 2). Unexpectedly, GABAAR-
mediated IPSCs actually tended to be larger in anti-GAD-treated
tissue compared to controls (Figures 2B–D). Indeed, the charge
transfer was doubled in cells from anti-GAD65-treated animals,
although this difference was not statistically different (Table 2).
Hence, our patch-clamp analyses of CA1 neurons confirmed
that neither amplitudes nor kinetics of GABAergic transmission
were changed in anti-GAD65-treated tissue compared to control
tissue.
Spontaneous GABAergic IPSCs Are not
Altered in Anti-GAD65 Tissue
We recorded also spontaneous inhibitory postsynaptic currents
(sIPSCs) in our patch-clamp experiments (Figure 3A). These
sIPSCs were completely blocked by gabazine (data not shown).
In total, we detected 643 sIPSCs in 306 s in control tissue
(8 cells) and 802 sIPSCs in 327 s in anti-GAD65 tissue (7
cells). On average, the sIPSC frequencies were not significantly
different between control (2.1 ± 0.3 Hz, n = 8 cells) and
anti-GAD65 tissue (2.5 ± 0.6 Hz, n = 7 cells). In addition,
no significant difference was obtained in sIPSC amplitudes
(Control: 30.2 ± 2.5 pA, n = 8; Anti-GAD: 41.5 ± 8.7 pA,
n = 7). Since calculating the mean frequency and the mean
amplitude might underestimate changes in the distribution of
sIPSCs, we next plotted histograms showing the frequencies and
relative proportions of sIPSCs in distinct classes of amplitudes
(Figures 3B,C). However, statistical evaluation using two-way
ANOVA only revealed significant differences between amplitude
classes (P < 0.05), but no significant treatment effect (i.e.,
Control vs. Anti-GAD). Hence, spontaneous IPSCs were not
altered in anti-GAD65 tissue as assessed by the mean frequency,
the mean amplitude and their distribution.
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FIGURE 2 | GABAA receptor-mediated inhibitory postsynaptic currents (IPSCs) are intact in anti-GAD65 tissue. (A) Superimposed sample traces showing
GABAA receptor-dependent IPSCs before (black trace) and after 5 µM gabazine (gray trace). Lowercase letters indicate the current at the holding potential (a),
stimulus artifact (b), GABAAR-mediated IPSC (c), and stimulation-evoked trace after gabazine (d). (B) Whole-cell patch-clamp recordings confirmed that IPSCs
evoked by near field stimulation were entirely GABAA receptor-dependent. (C) Input-output relationship of GABAAR-mediated IPSCs was not significantly different
between anti-GAD65 and control tissues. (D) The current-voltage relationship revealed that the reversal potential for GABAAR-mediated synaptic responses was
indistinguishable between anti-GAD65-treated animals and controls.
TABLE 2 | Kinetic properties of GABAA-receptor mediated IPSCs
(patch-clamp recordings).
Kinetic property Control (n = 7) Anti-GAD (n = 7) P value
Rise time constant (τrise) 3.6 ± 0.6 ms 4.0 ± 0.7 ms 0.76
Decay time constant (τdecay) 69.0 ± 7.3 ms 69.9 ± 1.2 ms 0.96
IPSC width at 10% 185.8 ± 17.5 ms 185.4 ± 26.2 ms 0.99
Latency 3.3 ± 0.3 ms 3.2 ± 0.3 ms 0.80
Charge (AUC) −42.6 ± 10.4 pC −87.1 ± 28.9 pC 0.20
Coefficient of variation 4.7 ± 0.9 % 4.1 ± 0.8 % 0.51
DISCUSSION
Antibodies against GAD of 65 kDa (anti-GAD65) in the CSF
have been described in patients with SPS (Solimena et al.,
1988), but also in a subgroup of patients with late-onset isolated
cerebellar ataxia (Honnorat et al., 2001) or limbic encephalitis
and epilepsy (Peltola et al., 2000; Saiz et al., 2008; Malter et al.,
2010). Since GAD65 is the key enzyme for GABA synthesis in
the CNS, the pathophysiological role of these antibodies has
commonly been ascribed to an inhibition of GABA synthesis and
thus GABAergic transmission (Dinkel et al., 1998). The present
study used in vivo stereotactic injection of human anti-GAD-
containing CSF into rat hippocampus. However, GABAergic
transmission remained intact in these slices arguing against
GABA depletion in anti-GAD65 treated animals.
What is the pathophysiological role of anti-GAD? Following
the demonstration that anti-GAD interacted with GABAergic
neurons, Dinkel et al. (1998) demonstrated that IgG in the sera
of SPS patients reduced GAD activity in crude rat cerebellar
extracts, leading to reduction in GABA synthesis. However, the
enzymatic activity was preserved when purified IgG from anti-
GAD-positive diabetic patients was used suggesting differential
epitope specificity of anti-GAD distinguishing neurological from
diabetic cases (Dinkel et al., 1998; Ishida et al., 1999; Manto
et al., 2007). In addition, electrophysiological data confirmed this
view, because IgG from an anti-GAD-positive patient with ataxia
suppressed inhibitory transmission onto cerebellar Purkinje
cells (Ishida et al., 1999; Mitoma et al., 2000, 2003). Similar
results were subsequently obtained in a patient with progressive
cerebellar ataxia, unresponsive to intravenous administration
of immunoglobulins, suggesting an irreversible damage to
cerebellar neurotransmission (Takenoshita et al., 2001). These
data suggest that—at least in cerebellar ataxia—down-regulated
GABA synthesis might disinhibit Purkinje cells and thus
contribute to the manifestation of the disease. There is only one
report on hippocampal neurons in culture, where anti-GAD-
positive sera were reported to interfere with GABA function and
consequently with neuronal inhibition (Vianello et al., 2008).
The pathophysiological role of anti-GAD in epileptic seizures
has not been addressed systematically before. However, it is
obvious that a relevant role of anti-GAD65 should imply a
dysfunction of GABAergic neurotransmission. In the present
study, intracellular as well as patch-clamp recordings from
CA1 neurons failed to detect amplitude or kinetic changes
of evoked GABA responses. Interestingly, in parallel to our
investigation, similar results were obtained in another group
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FIGURE 3 | Spontaneous IPSCs are not altered in anti-GAD65 tissue. (A) Sample traces of spontaneous IPSCs in control and anti-GAD65 tissue.
(B) Histogram showing the frequencies of distinct sIPSC amplitude classes revealing no difference in distribution. (C) Histogram showing the relative proportion of
sIPSC amplitude classes revealing again no difference in distribution.
using hippocampal slices cultures. In this preparation, incubation
with serum from an anti-GAD65 patient had no effect on evoked
or spontaneous GABAergic transmission (Stemmler et al., 2015).
Thus, dysfunction of phasic GABAergic transmission does not
play amajor role in governing epileptogenicity. This is in contrast
to the data of Ishida et al. (1999) studying cerebellar ataxia and
can be viewed as a strong argument against reduced GABA
synthesis in anti-GAD65 encephalitis-associated epilepsy.
What might be the pathophysiological role of anti-GAD65 in
epilepsy? In the present study, we have largely obtained negative
results using human CSF samples containing anti-GAD65. At
least, we have observed that the membrane resistance of CA1
neurons in anti-GAD65 tissue was substantially higher than
in control tissue. This implies a stronger voltage deflection
in response to transmembrane currents and may lead to
impaired shunting inhibition. On the other hand, gabazine
depolarized cells from anti-GAD65 tissue significantly stronger
than control cells arguing against this idea. Given the majority
of negative data, one might argue that we cannot be sure that
the antibodies have properly reached sufficient concentrations in
the tissue. Alternatively, the injected antibodies may have been
cleared from the tissue. Although we cannot entirely exclude
these issues, we believe that this is unlikely to be the case, because
we have conducted a separate study on anti-NMDAR CSF in
parallel to the experiments described here. By using undiluted
CSF samples from anti-NMDA receptor encephalitis patients,
we could demonstrate an NMDA receptor-specific phenotype
including impaired NMDA receptor-dependent transmission
and synaptic plasticity (Würdemann et al., 2016). Moreover,
impairment of NMDA receptor function was preserved for up
to 10 days after surgery. In addition, we also found differences
in the Morris water maze hidden platform task indicating an
altered hippocampus-dependent spatial learning and suggesting
that a single stereotactic injection of CSF can exert behavioral
effects for up to 2 weeks (Würdemann et al., 2016). This
study demonstrated that diffusion or clearance of antibodies
in the hippocampal parenchyma appears to occur on a very
slow timescale. Since we used undiluted CSF samples in these
experiments as in the present study, we believe that the negative
results obtained here do suggest that anti-GAD65 has no effect on
GABAergic synaptic transmission which is in line with previous
reports (Stemmler et al., 2015; Werner et al., 2015).
Nevertheless, there is at least one alternative explanation
of anti-GAD65 effects on neurons, again derived from data
on SPS or cerebellar ataxia. Using a combined microdialysis
and electromyography approach, Manto et al. (2007) showed
that anti-GAD65 decreased the NMDA receptor-mediated
NO production and thus impaired the synaptic regulation
of glutamatergic transmission. At cerebellar synapses, NO
inhibits the presynaptic glutamate release, and anti-GAD65
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hence resulted in increased concentrations of glutamate in
deep cerebellar nuclei. On the functional level, anti-GAD65
administration in vivo caused continuous motor activity with
repetitive discharges, abnormal exteroceptive reflexes, and
increased excitability of anterior horn neurons (Manto et al.,
2007).
All in all, the pathophysiological role of anti-GAD65 is
not unequivocal. One major argument against a direct role is
that GAD65 is an intracytoplasmic enzyme both in neuronal
and pancreatic cells, which is not exposed on the cytoplasmic
membrane during GABA release. Under certain circumstances
at least, antibodies may reach intracellular targets. While ability
of IgG to enter neurons has already been mentioned more than
20 years ago (Fishman et al., 1990, 1991; Yanase et al., 1994), only
recent work has demonstrated that IgG can be internalized by
neurons, making intracellular antigens accessible in experimental
settings (Geis et al., 2010). Hence, albeit antibodies may reach
intracellular targets, it appears to be a rare phenomenon and it
is unclear whether this mechanism is also relevant in the in vivo
condition. An alternative explanation could be that anti-GAD65
antibodies cross-react with another, yet unknown target, which
is approachable on the neuronal surface, such a mechanism
has been described for anti-nuclear antibodies (Madaio et al.,
1996). Furthermore, additional antibodies might coexist with
the initially identified antibodies. At least in SPS, additional
antibodies such as anti-GABAB-receptor have been described
(Lancaster et al., 2010; Boronat et al., 2011). Importantly,
in the presence of IgG from SPS GABAergic transmission
and presynaptic GABAergic vesicle pool size were preserved
(Werner et al., 2015). A further argument against a pure GAD-
inhibiting effect of anti-GAD65 is derived from the diversity
of anti-GAD-associated disorders such as neurological and
diabetic manifestations. Even more intriguing, but completely
unresolved is the fact that some neurological patients with
anti-GAD65 develop epileptic seizures, while other suffer from
cerebellar ataxia or SPS. This would be difficult to explain if all
autoantibodies in these conditions had the same effect—namely
blocking GAD enzyme activity.
In summary, we show that CSF containing GAD65-antibodies
does not alter GABAergic transmission as proposed for cerebellar
manifestations of anti-GAD65 related disorders. Since GAD65-
antibodies may show a high variability with respect to their
biological effects and pathological sequelae, there is certainly
a need to gather further serum or CSF samples in these
rare diseases in order to unravel the complex molecular
pathophysiology of anti-GAD65 autoimmunity.
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